PD increases hERG1 current by multiple effects, including a shift of inactivation to a more positive voltage, slowing of deactivation and an increase in single channel open probability. The efficacy of PD was increased in proportion to the WT:L646E subunit ratio. The Hill coefficient was 1.40 -1.55 for all the heteromeric concatamers, suggesting a weak positive cooperativity for PD binding. At a fully effective concentration of PD (10mM), each WT binding site contributes~20% towards the maximum response of 80% enhancement of current. ICA increases hERG1 current by a profound attenuation of inactivation. An increase in the WT:F557L subunit ratio enhanced the agonist activity of ICA (10mM and 30mM) in a synergistic fashion. For 2WT/2F557L concatenated channels, synergy required adjacent (as opposed to diagonal) WT subunits. In summary, four intact binding sites per channel are required to fully activate hERG1 by PD or ICA. Human ether-a-go-go related gene (hERG) channel inhibitors can be trapped in the channels at rest. The structural peculiarities of hERG blockers that enable trapping or alternatively resting state dissociation are currently unknown. Propafenone (small molecule, MW 341 g/mol) is efficiently trapped in the closed hERG channel pore (1). To investigate whether the size of the blocking molecule plays a role in trapping we synthesized bulky propafenone derivatives containing benzoyl and trimethylphenyl side chains, attached by piperazine linkers, with molecular weights of 500 (Fba212) and 650 g/mol (Fba213) respectively. hERG channels were expressed in Xenopus laevis oocyte and potassium current inhibition was studied using the two -microelectrode voltage clamp technique. It was found: first, both compounds are potent hERG blockers with IC50 3.7mM (Fba212) and 52mM (Fba213). Secondly, channel block by Fba212 and 213 was prevented by mutations Y652A and F656A as previously shown for propafenone. Third, both propafenone derivatives were trapped at rest. To obtain insights into the molecular mechanism of channel block docking experiments with Fba212 and Fba213 in closed and open conformation were performed. Both compounds interact with the propafenone binding site (Y652A and F656A). Fba213 was found to exceed the size of the closed channel cavity of our hERG homology model. We conclude that drug trapping in hERG channels does not necessarily require full closure of the activation gate. University of Vienna, Vienna, Austria. ICA105574 (3-Nitro-N-(4-phenoxyphenyl)-benzamide) activates hERG1 (Kv11.1) channels by reducing inactivation, but inhibits hEAG1 (Kv10.1) channels by inducing inactivation. using chimeric ERG-EAG constructs, we found that the channel-specific response to ICA105574 is mediated by the pore region (S5-pore helix-S6). Simulated docking of ICA105574 on a molecular model of hEAG1 coupled with alanine mutagenesis indicates that similar to hERG1, ICA105574 binds to a hydrophobic region confined by the S5/S6/ pore helix of one subunit and S6 of adjacent subunit in hEAG1 channels. Based on the putative ICA binding site and protein sequence alignment, a triple mutant of hEAG1 (M431F/M458L/L463M hEAG1) was designed to make the ICA binding region in hEAG1 homologous to hERG1. ICA inhibited the triple mutant similar to WT-hEAG1, indicating that the amino acid differences within the putative ICA binding region do not determine the reciprocal functional response to ICA. A single mutation in S5 (F557L), pore helix (L622C) or S6 (Y652A) of hERG1 eliminates the activity of ICA on hERG1 (Garg, et al 2011, Mol. Pharm.). The equivalent mutations in hEAG1 affect inactivation differentially and result in very different responses to ICA. First, Y464A induced inactivation of hEAG1 channels and this gating was accentuated by ICA. Second, ICA is a partial agonist of F359L and L434C mutant channels. We recently proposed a tripartite model of slow inactivation for hEAG1 that involves interaction of the same three residues. We conclude that ICA binds to the same site in hEAG1 and hERG1 channels, and that the functional consequences are determined by the underlying (fast or slow) mode of selectivityfilter mediated inactivation.
1367-Pos Board B259
Inactivation Properties, not Binding Site Differences, Govern Reciprocal Functional Response to ICA105574 in EAG and ERG Potassium Channels Vivek Garg 1 , Anna Stary-Weinzinger 2 , Michael C. Sanguinetti 1 .
1 University of Utah, Salt Lake City, UT, USA, 2 University of Vienna, Vienna, Austria. ICA105574 (3-Nitro-N-(4-phenoxyphenyl)-benzamide) activates hERG1 (Kv11.1) channels by reducing inactivation, but inhibits hEAG1 (Kv10.1) channels by inducing inactivation. using chimeric ERG-EAG constructs, we found that the channel-specific response to ICA105574 is mediated by the pore region (S5-pore helix-S6). Simulated docking of ICA105574 on a molecular model of hEAG1 coupled with alanine mutagenesis indicates that similar to hERG1, ICA105574 binds to a hydrophobic region confined by the S5/S6/ pore helix of one subunit and S6 of adjacent subunit in hEAG1 channels. Based on the putative ICA binding site and protein sequence alignment, a triple mutant of hEAG1 (M431F/M458L/L463M hEAG1) was designed to make the ICA binding region in hEAG1 homologous to hERG1. ICA inhibited the triple mutant similar to WT-hEAG1, indicating that the amino acid differences within the putative ICA binding region do not determine the reciprocal functional response to ICA. A single mutation in S5 (F557L), pore helix (L622C) or S6 (Y652A) of hERG1 eliminates the activity of ICA on hERG1 (Garg, et al 2011, Mol. Pharm.) . The equivalent mutations in hEAG1 affect inactivation differentially and result in very different responses to ICA. First, Y464A induced inactivation of hEAG1 channels and this gating was accentuated by ICA. Second, ICA is a partial agonist of F359L and L434C mutant channels. We recently proposed a tripartite model of slow inactivation for hEAG1 that involves interaction of the same three residues. We conclude that ICA binds to the same site in hEAG1 and hERG1 channels, and that the functional consequences are determined by the underlying (fast or slow) mode of selectivityfilter mediated inactivation.
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Rehabilitation Studies for withdrawn Drugs from the Market: Derivation of Non-hERG1 Channel Blocker Cisapride Analogues using Multi-Faceted Approaches Serdar Durdagi, Trevor Randal, Henry J. Duff, Sergei Y. Noskov. University of Calgary, Calgary, AB, Canada. The human ether-a-go-go related gene 1 (hERG1) potassium ion channel is a key element for the cardiac delayed rectified potassium current IKr and it plays an important role in the normal repolarization of the action potential. Diverse types of organic compounds used both in common cardiac and noncardiac medications can reduce the IKr and may lead to ventricular arrhythmia. Therefore, several approved drugs have been withdrawn from the market because of their effects on QT interval prolongation. Since most of these drugs have high potency for their principal targets, ''rehabilitation'' studies for decreasing their high hERG1 blocking affinities while keeping them active at the binding site of their targets may lead re-use of these drugs. For this aim, a gastroprokinetic agent, cisapride, is studied. Cisapride is withdrawn from the market because of its high hERG1 blocking affinity. In this study, analyses of fragment interactions of cisapride at the human A2A adenosine receptor and hERG1 central cavities is investigated using in silico applications (molecular docking, molecular dynamics simulations, de novo drug design) and novel and safer (with low hERG1 blocking affinities) of cisapride derivatives are proposed for their synthesis and their biological tests. The human Ether-a-go-go Related Gene (hERG) encodes Kv11.1 and underlies the rapidly activating delayed rectifier K þ current in the heart, and loss-offunction hERG mutations cause the type 2 long QT syndrome (LQT2). The majority of LQT2-linked missense mutations decrease the trafficking of Kv11.1. An important finding is drugs that bind to Kv11.1 and block current (IKv11.1) can correct the trafficking for most of these mutations (pharmacological correction). We tested the hypothesis that pharmacological correction increases the trafficking of mutant LQT2 channels from the Endoplasmic Reticulum (ER). Voltage-clamping and Western blotting experiments of HEK293 cells expressing the trafficking-deficient LQT2 mutation G601S showed that pharmacological correction still occurred in cells treated with the protein synthesis inhibitor cycloheximide. Confocal analyses of HEK293 cells stably expressing wild type Kv11.1 or G601S showed that G601S is selectively stored in an intermediate ER compartment with BAP31. The intermediate BAP31 compartment does not overlap with the perinuclear ER compartment, transitional ER compartment, or the ER Golgi Intermediate Compartment. Treating cells in E-4031, a drug that corrects G601S trafficking, decreased G601S co-localization with intermediate BAP31 compartment and increased G601S immunostaining at the cell surface membrane. Additional experiments showed that treating cell in E-4031 for as little as 30 min was sufficient to caused the pharmacological correction of IKv11.1 for many hours. Together these data demonstrate that a steady-state subpopulation of LQT2 channels is stored separately in the BAP31 transitional ER compartment and their functional expression is readily corrected by E-4031 treatment.
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1370-Pos Board B262 LQT2 Nonsense Mutations Generate Trafficking Deficient N-Terminally Truncated Channels by the Reinitiation of Translation Matthew Stump, Qiuming Gong, Zhengfeng Zhou. OHSU, Portland, OR, USA. Long QT syndrome type 2 (LQT2) is caused by mutations in the human ethera-go-go related gene (hERG). The reinitiation of translation has recently been reported as a novel pathogenic mechanism of LQT2 by which early PTC mutations generate N-terminally truncated channels with altered gating properties. We have previously shown that hERG transcripts containing the Q81X mutation were translated at the downstream M124 codon following premature termination and generated channels that exhibited increased deactivation kinetics and decreased resurgent outward current during action potential repolarization. We have now identified two additional LQT2 nonsense mutations C39X and C44X that escape nonsense mediated mRNA decay by the reinitiation of translation. Unlike the Q81X channels, which are expressed at the cell surface, 266a C39X and C44X channel proteins are trafficking defective. We show that C39X and C44X channels undergo translation reinitiation at M60 which deletes the hERG N-terminus including the first 34 residues of the Per, Arnt, and Sim (PAS) domain. In contrast to the reinitiation of Q81X channels at M124, in which the PAS domain is nearly completely deleted, reinitiation at M60 disrupts the folding of this highly structured domain, precluding the efficient folding and trafficking of the mutant channels. The RNase protection assay, western blot analysis and electrophysiology were used to characterize the LQT2 mutants at the RNA, protein, and functional level. Our findings indicate that translation reinitiation may give rise to trafficking as well as functional defects of mutant hERG channels associated with LQT2 nonsense mutations.
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Non-Coding Data in KCNH2 mRNA Control Translation and Trafficking Efficiencies Jakub Sroubek, Yamini Krishnan, Thomas V. McDonald. Albert Einstein College of Medicine, Bronx, NY, USA. The KCNH2 gene encodes a Kþ channel important to normal cardiac electrophysiology. Its significance is underscored by its link to both hereditary (locus LQT2) and acquired Long-QT cardiac arrhythmias. Over 400 deleterious mutations have been reported throughout the KCNH2 length. Why the channel is so susceptible to missense mutations is unclear. More than 50% of LQT2 mutations result in defective assembly and trafficking. There is evidence that even wild type channels are processed inefficiently. It has also been reported that the channel protein may reach the surface via atypical pathways. Most attention has logically focused on the protein for these processes. Much less is known about mRNA-dependent factors in channel processing. We analyzed the coding mRNA sequence of KCNH2. It has 66% GC content and 60 potential hair-pin loop segments. We re-synthesized the cDNA to achieve 50% GC-content and reduce the number of potential hair-pin loops while maintaining identical amino acid coding. Cellular expression of the codon-modified cDNA (CM-KCNH2) produced ionic currents comparable to native cDNA. Channel protein was expressed in a dramatically different pattern. Whereas the native protein (NT-KCNH2) is usually more abundant (immature form) in ER/Golgi compartments than on the surface, CM-KCNH2 showed a preponderance of the mature form, indicating channels at the surface. Immunofluorescence analysis confirmed this localization. From these results we hypothesize that KCNH2 translation efficiency, determined by RNA sequence-specific elements independent of coding, affect downstream protein assembly and/or trafficking_an unusual occurrence. As a corollary to this, we postulate a synergy between the inherently inefficient biosynthesis of KCNH2 and LQT2 mutations that contribute to the pathogenesis of hereditary LQT2. Further investigation of mechanisms underlying mRNA-dependent processing of KCNH2 channels may lead us to reconsider approaches to hereditary and acquired arrhythmia syndromes.
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Interactions of Extracellular Potassium, Calcium, Magnesium and Hydrogen with the outer Pore of the Cardiac Potassium Channel hERG Shaun Rafael, Eric Lau, Ryan Fraiser, Vincent Carbone, Kevin Ha, Vikram Makhijani, Attilio Macrito, Eddie Thara, Nicholas Logemann, Alan Miller. Touro University -California, Vallejo, CA, USA. Reduction of the current carried by the cardiac potassium channel HERG can lead to Long QT syndrome, an arrhythmia characterized by a rapid heart rate and reduced cardiac output, which can, in certain situations, be fatal. The effect of extracellular electrolytes on the biophysical properties of the HERG channel have been studied in some detail. In particular, increases in extracellular calcium, magnesium and hydrogen have been shown to slow channel activation, increase channel deactivation, and shift the G-V curve to more positive voltages. A number of reports have also shown that hydrogen can reduce HERG current by a mechanism that does not involve an effect on channel deactivation and which likely involves pore block. We show here that reducing extracellular potassium results in a significant increase in HERG current reduction by extracellular calcium, hydrogen, and magnesium. Current reduction by calcium appears to be significantly greater than current reduction by magnesium. Furthermore, the reduction in HERG current by extracellular hydrogen depended on the extracellular calcium concentration. The Drosophila voltagegated potassium channel Shaker, showed a much smaller decrease in current by extracellular calcium and this effect was not dependent on extracellular potassium. In addition there was no difference in current reduction by calcium between WT HERG and the inactivation deficient mutant S631A, either in low or high extracellular potassium. These results suggest that calcium, hydrogen, and magnesium can block the HERG potassium channel and that calcium, hydrogen, magnesium, and potassium may interact at the outer pore of the HERG channel.
1373-Pos Board B265 Structural Basis for Differential KCNQ1 Interactions with KCNE1 and KCNE2 in the Extracellular Juxtamembrane Region Mei Zhang, Yuhong Wang, Min Jiang, Gea-Ny Tseng. Virginia Commonwealth University, Richmond, VA, USA. KCNE1 and KCNE2 are both expressed in human heart and can associate with KCNQ1. KCNE1 and KCNE2 share transmembrane topology and sequence homology, yet they differ in KCNQ1 modulation (KCNE1 slows KCNQ1 Closedto-Open transition, while KCNE2 slows KCNQ1 Open-to-Closed transition) and pharmacology (KCNQ1/KCNE2 is 5 and 10 fold less sensitive than KCNQ1/KCNE1 to niflumic acid, I Ks activator, and azimilide, I Ks suppressor). Previous work has shown that the extracellular juxtamembrane (EJM) region of KCNE1 interacts with the extracellular surface of KCNQ1 to modulate gating kinetics and to form I Ks activator binding sites. This prompts us to compare the EJMs of the two KCNE subunits in terms of KCNQ1 interaction. We apply cysteine (Cys) scanning mutagenesis to EJMs of KCNE1 and KCNE2 and analyze the patterns of functional perturbation when coexpressed with KCNQ1. We use methanethiosulfonate (MTS) reagents to probe the relationship between EJMs of KCNE subunits and KCNQ1. Finally we probe disulfide formation between Cys engineered into the EJMs of KCNE subunits and those engineered into extracellular surface of KCNQ1. The EJM of KCNE1 makes frequent contacts with KCNQ1, so that MTS modification of exposed Cys side chains can affect channel gating. KCNQ1/KCNE2 is largely indifferent to MTS modification of exposed Cys side chains engineered to EJM of KCNE2. However, MTS can slowly access 7 consecutive hydrophobic positions in the beginning of KCNE2 transmembrane domain, as if there is a crevice between KCNQ1 and KCNE2. Disulfide trapping experiments suggest that KCNE2 is leaning more toward KCNQ1 S2 than KCNE1. We propose that KCNE2 interferes with S2-S4 interactions during KCNQ1 Open-to-Closed transition and thus slows deactivation. This weakens sensitivity to niflumic acid and azimilide by affecting binding site directly or by an allosteric mechanism.
